Idiopathic Transverse Myelitis and Neuromyelitis Optica: Clinical Profiles, Pathophysiology and Therapeutic Choices
2011
Idiopathic Transverse Myelitis and Neuromyelitis Optica: Overview and Treatment Options
publication
Evidence: moderate
Author Information
Author(s): Awad Amer, Stüve Olaf
Primary Institution: Case Western Reserve University, University of Texas Southwestern Medical Center
Conclusion
The study reviews the clinical profiles, pathophysiology, and treatment options for idiopathic transverse myelitis and neuromyelitis optica.
Supporting Evidence
- The annual incidence of transverse myelitis in the U.S. is around 4.6 per million.
- Idiopathic transverse myelitis may be associated with a risk of developing multiple sclerosis.
- Treatment options include corticosteroids, plasma exchange, and immunosuppressive therapies.
Takeaway
This study talks about two diseases that affect the spinal cord and eyes, explaining how they happen and how they can be treated.
Methodology
The study reviews existing literature on the epidemiology, clinical profiles, pathophysiology, and treatment options for transverse myelitis and neuromyelitis optica.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website